Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Annexon Inc ANNX

Healthcare Biotechnology
Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ANNX)

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 9 days ago

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

GlobeNewswire 10 days ago

Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting

GlobeNewswire December 5, 2024

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 15, 2024

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

GlobeNewswire November 14, 2024

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

GlobeNewswire November 13, 2024

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

GlobeNewswire October 21, 2024

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 16, 2024

Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

GlobeNewswire October 15, 2024
View More News ››

Opinion & Analysis (NDAQ:ANNX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ANNX)

Annexon Provides Update on ARCHER II Global Registrational P

NEWS: $ANNX Annexon Provides Update on ARCHER II Global Registrational Program in Geographic AtrophyPatient Dosing Initiated in Phase 3...
whytestocks - August 5, 2024

Annexon Announces Pricing of $125 Million Underwritten Publi

Breaking News: $ANNX Annexon Announces Pricing of $125 Million Underwritten Public OfferingBRISBANE, Calif., June 05, 2024 (GLOBE...
whytestocks - June 5, 2024
View more Bullboard ››

Silvercorp Metals Inc.

Silvercorp Metals Inc.

Silvercorp is a Canadian mining company producing silver, gold, lead, and zinc with a long history of profitability and ...
View More »